Last reviewed · How we verify
NCT05312736: GYROS
Gyrate Atrophy Ocular and Systemic Study
trial in Gyrate Atrophy in 46 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2028
Quick facts
| Lead sponsor | Jaeb Center for Health Research |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 46 |
| Start date | 21 November 2023 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 11 locations across France, Italy, Finland, United Kingdom, Germany, Canada, United States, Brazil |
Conditions studied
- Gyrate Atrophy — all drugs for Gyrate Atrophy →
- Gyrata of Choroid and Retina; Atrophy — all drugs for Gyrata of Choroid and Retina; Atrophy →
- Ornithine-δ-aminotransferase — all drugs for Ornithine-δ-aminotransferase →
- OAT — all drugs for OAT →
Sponsor
Jaeb Center for Health Research — full company profile →
Who can join
12 and older, any sex, with Gyrate Atrophy or Gyrata of Choroid and Retina; Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Gyrate Atrophy Ocular and Systemic Study characterizes the natural history of ornithine levels and retinal degeneration (RD) associated with disease-causing OAT variants in the presence of standard care dietary treatment regimens over 4 years. The research goal is to understand the impact of OAT mutations on plasma ornithine levels and retinal degeneration. Funding Source- FDA OOPD
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Inherited Retinal Degenerations and Non-Neovascular Age-Related Macular Degeneration: Progress and Unmet Needs.
Duncan JL, Bowman A, Laster A, Gelfman C, et al · · 2024 · cited 5× · PMID 39688851 · DOI 10.1167/tvst.13.12.28 -
Molecular and cellular mechanisms underlying gyrate atrophy: Why is the retina primarily affected?
Buijs MJN, Balfoort BM, Brands MM, Ten Asbroek ALMA, et al · · 2025 · cited 2× · PMID 40192087 · DOI 10.1111/aos.17498 -
A novel phenotype-guided genome analysis pipeline for variant discovery.
Ahmed L, Tavares E, Li JM, Ahmed K, et al · · 2026 · PMID 41904215 · DOI 10.1038/s41525-026-00557-0
Verify or expand the search:
- PubMed search for NCT05312736
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Jaeb Center for Health Research trials
Trials by the same sponsor.
- NCT07496515 — Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia · Phase 2 · not yet recruiting
- NCT07095894 — A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control · Phase 3 · not yet recruiting
- NCT06837181 — Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) · recruiting
- NCT06880835 — Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automate · NA · recruiting
- NCT06957028 — CGM for the Early Detection and Management of Hyperglycemia in Pregnancy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05312736 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jaeb Center for Health Research
- Last refreshed: 26 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05312736.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing